EXEL

Exelixis, Inc.

HALAL

Score: 87/100

stock

Is EXEL Halal?

Commercial-stage oncology-focused biopharmaceutical company — permissible life-saving-pharmaceutical business with strong Sharia-compliance profile.

What You Should Know

Exelixis, Inc. is a commercial-stage oncology-focused biopharmaceutical company anchored by the cabozantinib franchise — sold under the Cabometyx brand for advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and differentiated thyroid cancer indications, and historically under the Cometriq brand for medullary thyroid cancer. Cabometyx is one of the leading global treatments in the second-line and combination-therapy renal-cell-carcinoma market, with combination-therapy approvals alongside immune-checkpoint inhibitors (Bristol-Myers Squibb's Opdivo) materially expanding the addressable population. Exelixis also commercializes Cotellic (cobimetinib) in melanoma combination therapy under a partnership with Genentech/Roche, and develops a pipeline of next-generation oncology assets including zanzalintinib (XL092 — a next-generation tyrosine-kinase inhibitor in late-stage colorectal-cancer, renal-cell-carcinoma, and other oncology trials), XB002 (a tissue-factor antibody-drug conjugate), and a broader portfolio of small-molecule and antibody-drug-conjugate oncology assets. International commercialization of cabozantinib is partnered with Ipsen (ex-US ex-Japan) and Takeda (Japan). Oncology-pharmaceutical research, development, and commercialization is unambiguously permissible at the activity level under standard Sharia methodology — pharmaceutical activities aimed at preserving life (hifz al-nafs) are explicitly aligned with the higher objectives of Sharia (maqasid). The financial screen passes comfortably: Exelixis operates a substantial net-cash balance sheet with no meaningful debt, and the debt-to-market-cap ratio sits well below the 33% Sharia threshold. Most major Sharia advisory boards classify Exelixis as permissible with purification of small interest-income components.

⚠️ Concerns

•Interest income on cash and short-term investment balances — Exelixis carries a substantial net-cash position and interest income may be a non-trivial component of other-income relative to a smaller-cap biotech; verify against the 5% revenue threshold at the time of investment and apply purification of a small portion of any dividends or distributions, though Exelixis does not currently pay a regular dividend
•Cabozantinib franchise concentration risk — the majority of current revenue is derived from the Cabometyx franchise; pipeline-asset development success will determine the durability of the franchise as the cabozantinib composition-of-matter patent estate eventually erodes
•Clinical-trial outcome variance — late-stage oncology trial readouts (including zanzalintinib in colorectal cancer and other indications) introduce binary-outcome risk; this is a business-investment consideration rather than a Sharia screen concern
•Some pharmaceutical research activities may involve animal-derived materials or biological samples in research processes — these are general-purpose biomedical-research considerations rather than direct-product concerns
•Pricing-and-access debates in pharmaceutical reimbursement may surface periodically — these are policy-and-political considerations rather than Sharia screen concerns